to Press Release List
BELLEVUE, Wash., USA – Advanced
Renal Technologies (www.advrenaltech.com), developers of
Citrasate® and DRYalysate® citric acid-based dialysate
concentrates, announced today they will have exhibit booth
2.08b, adjacent to Fresenius, at the ERA-EDTA Annual Congress,
May 15-18, 2004 in Lisbon, Portugal.
“ART is excited to
be a part of Europe’s premier nephrology meeting,”
said Mike Fulton, managing director. “As a developer
of innovative technologies, ART relies on international
meetings such as ERA-EDTA to make important contacts to
partner with high quality manufacturers, distributors and
academic partners throughout the world. We are keen to establish
partnerships in Europe, Middle East, Asia and Latin America.”
Citrasate and DRYalysate are patented
acid concentrates using citric acid, a known anticoagulant.
ART’s citric acid-based dialysate concentrates are
particularly helpful in better dialysis for those patients
where heparin is contraindicated, such as heparin antibodies
or allergies. The acid concentrate products are also helpful
in acute dialysis where there is a risk of bleeding or clotting.
Citrasate and DRYalysate have been shown to prevent dialyzer
clotting, reduce metabolic acidosis and increase reuse of
Advanced Renal Technologies (ART)
is focused on the development of novel and innovative therapeutics
to improve the treatment of patients with acute and chronic
kidney failure in hospital, home and outpatient dialysis
facilities. More information about ART may be found at www.advrenaltech.com,
or by contacting Mike Fulton at +1-425-453-8777.